Summary
HIV fusion inhibitors are peptide therapeutics that block the entry of HIV into host cells by preventing the conformational changes required for viral-cell membrane fusion. Understanding peptide stability and structural behavior in physiological fluids (serum, plasma) is critical for predicting bioavailability and degradation by proteases.
This application note demonstrates time-resolved SAXS characterization of an HIV fusion inhibitor peptide (4.5 kDa, 38 residues) in three different environments: saline formulation, serum-saline mixture, and plasma-saline mixture. The challenge was measuring peptide signal against extremely strong background scattering from serum/plasma proteins, requiring dedicated data-collection strategies.
Background & Challenge
HIV Fusion Inhibitors
HIV fusion inhibitors are synthetic peptides that mimic portions of HIV gp41 protein:
- Mechanism: Bind to viral envelope protein preventing membrane fusion
- Size: Typically 36-40 amino acids (~4-5 kDa)
- Structure: Must maintain α-helical conformation for activity
- Clinical example: Enfuvirtide (T-20/Fuzeon®)
Pharmaceutical Challenge
Understanding peptide behavior in biological fluids is critical for:
- Activity prediction: Structure-function relationship in vivo
- Stability assessment: Resistance to degradation in serum
- Protein binding: Interactions with albumin and other serum proteins
- Formulation design: Maintaining active conformation
- PK/PD modeling: Understanding distribution and clearance
Methods & Experimental Design
Sample Information
Peptide: HIV fusion inhibitor drug candidate (4.5 kDa, 38 amino acid residues)
Concentration: 5 mg/mL in formulation
Environments tested:
- Saline formulation (control)
- Saline + human serum mixture
- Saline + rat plasma mixture
Challenge: Serum and plasma produce extremely strong background scattering, requiring dedicated data-collection strategy to register peptide signal with sufficient accuracy.
Time-Resolved SAXS Protocol
Measurement Strategy
- Saline formulation2-hour time slices over 24 hours
- Serum-saline formulation2-hour time slices over 24 hours
- Plasma-saline formulation0.5-hour time slices over 6 hours
- AnalysisPDDF reconstruction, structural evolution
SAXS Measurement
Instrument Parameters
- X-ray sourceCu Kα
- InstrumentLaboratory SAXS at DANNALAB
- Q range0.05-4.3 nm⁻¹
Results
Result 1: Saline Formulation (Control)
Stable Structure Over 24 Hours
Within the 24-hour observation period, the saline formulation exhibited relatively stable structure. The volume and molecular aggregate weight were approximately four times greater than expected from the known crystallographic model of similar peptides, indicating oligomer formation.
Conclusion: Peptide forms stable aggregates in saline, maintaining structure without degradation for at least 24 hours.
Result 2: Serum-Saline Formulation
Topological Transformation After 12 Hours
Results showed the appearance of two different types of aggregates and a change in topology occurring after approximately 12 hours:
- First 12 hours: Type "A" aggregates formed
- After 12 hours: Transformation to Type "B" aggregates (dendrite-type structure)
- PDDF patterns: Similar changes observed in pair distribution functions after first 12 hours
Conclusion: Structure exhibits topological transformation to dendrite-type aggregates after ~12 hours of observation in serum environment.
Result 3: Plasma-Saline Formulation
Rapid Structural Changes
Results over 6 hours showed significant structural changes:
- Within first 0.5 hours: Initial structural change detected
- After 2.5 hours: Further transformation observed
- After 6 hours: PDDF analysis indicates strongly elongated structures with maximum dimension of approximately 22 nm
Note: Data quality in plasma was insufficient for reliable reconstruction of detailed structural features, but PDDF function clearly shows progression to elongated structures.
Conclusion: Plasma environment induces rapid and more extensive structural changes compared to serum.
Figure 1. The reconstructed peptide structures in the saline formulation obtained with 2 hr time slices within the 24 hr period.
Figure 2. Change in the PDDF function patterns observed after the first 12 hrs in serum/saline formulation.
Figure 3. Change in PDDF function patterns observed after the first 0.5 hr and 2.5 hrs in plasma/saline formulation.
Summary
Based on the SAXS experiments, time-resolved structural changes for the peptide drug candidate were reported in three different types of environment:
- Saline formulation: Structure exhibited stability within 24 hours
- Serum/saline formulation: Topological changes observed after 12 hours
- Plasma/saline formulation: Topological changes observed after 0.5 hours and 2.5 hours
* PDDF is a self-correlation function of relative scattering density within the particle. Maximums of the PDDF function show the most populated vectors inside the particles connecting the areas with the largest scattering density.
Download Full Conference Presentation
This research was presented at TIDES 2012 (Therapeutic Innovation & Development of Peptides & Proteins) in collaboration with Johnson & Johnson Pharmaceutical R&D and Malvern Panalytical. Download the complete presentation for additional figures, PDDF reconstructions, plasma formulation data, and comprehensive methodology.
Download TIDES 2012 Presentation (PDF)Collaborative work: V. Kogan (DANNALAB), Johnson & Johnson Pharmaceutical Research team, and PANalytical. Includes reconstructed 3D structures, time-resolved PDDF analysis, and stability studies in serum and plasma.